THE ROLE OF ROSUVASTATIN AND EZETIMIBE IN REDUCING MYOCARDIAL INFARCTION RISK
DOI:
https://doi.org/10.5281/zenodo.17383649Abstract
Atherosclerosis remains a leading cause of ischemic heart disease (IHD) and subsequent heart failure (HF). The progression of atherosclerosis involves lipid accumulation, endothelial dysfunction, and chronic vascular inflammation, leading to plaque formation and vascular stenosis. In young and middle-aged adults, dyslipidemia and subclinical vascular changes have become increasingly common due to sedentary lifestyles, dietary habits, and metabolic disorders.
Statins—particularly rosuvastatin—and cholesterol absorption inhibitors such as ezetimibe have shown significant efficacy in lipid control and atherosclerotic plaque stabilization. Their combined use may reduce the risk of myocardial infarction (MI) and improve vascular function, particularly in patients with residual risk despite statin monotherapy.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
By submitting a paper to the conference organized by Academic Publishing House, the author(s) agree to the following license terms and conditions:
1. Copyright and Licensing
-
The author(s) retain the copyright of their article.
-
The author(s) grant Academic Publishing House a non-exclusive license to publish, distribute, and archive the submitted material in both electronic and print formats.
-
The work will be published under the Creative Commons Attribution (CC BY 4.0) license, allowing others to share and adapt the material for any purpose, provided proper credit is given to the original author(s).
2. Author’s Responsibilities
-
The author(s) guarantee that the submitted work is original, does not infringe any existing copyrights, and has not been published or submitted elsewhere.
-
The author(s) confirm that all co-authors have approved the final version of the manuscript and agree with its submission and publication.
-
The author(s) are fully responsible for the accuracy of the data, citations, and references provided in the article.
3. Publisher’s Rights
-
Academic Publishing House reserves the right to edit, format, and make minor grammatical or layout corrections to the paper without altering its core content.
-
The publisher has the right to include the article in indexing databases, archives, and repositories such as Google Scholar, Zenodo, OpenAIRE, and other partner platforms.
-
The publisher may promote the paper through its website and official social media channels.
4. Open Access Policy
All conference papers are published as open access, ensuring free and permanent online access to the full text of all articles immediately upon publication.
5. Withdrawal and Retraction
If ethical misconduct, plagiarism, or data manipulation is detected, Academic Publishing House reserves the right to withdraw or retract the publication at any stage.
6. Acceptance of Terms
Submission of a manuscript to the conference implies that the author(s) have read, understood, and accepted these License Terms.
